Form 4: Verona Pharma Director Austwick Receives 96,000 Restricted Share Units

Michael Austwick, a director of Verona Pharma plc, was granted 96,000 Restricted Share Units (RSUs) on April 25, 2025, which vest in installments over the next year.

Summary

• On April 25, 2025, Michael Austwick, a director of Verona Pharma plc, received an award of 96,000 Restricted Share Units (RSUs).
• Each RSU represents the right to receive one American Depositary Share (ADS), and each ADS represents eight ordinary shares of Verona Pharma.
• The RSUs will vest in four equal installments of 25% each, on August 1, 2025, November 1, 2025, February 1, 2026, and May 1, 2026.
• Vesting is contingent upon Austwick's continued service to Verona Pharma on each of those dates.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of RSUs is a standard practice and indicates confidence in the company's future performance, but it's not a major event.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.

Risks

• The vesting of the RSUs is contingent upon continued service, so Austwick's departure from the company would result in forfeiture of unvested units.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

Granting stock-based compensation is a common practice in the pharmaceutical industry to attract and retain key personnel and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock options and restricted stock units are frequently used in the pharmaceutical industry as part of executive compensation packages.
• Companies like AstraZeneca, GlaxoSmithKline, and Novartis also utilize similar equity-based compensation plans to incentivize their executives.
• The vesting schedule of these RSUs (quarterly over a year) is fairly standard.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Verona Pharma, Restricted Share Units, RSU, Director, Michael Austwick, Beneficial Ownership, Form 4, VRNA